Evidence from a meta-analysis for the prognostic and clinicopathological importance of DKC1 in malignancies.

Aim: We conducted a meta-analysis to evaluate the prognostic and clinicopathological relevance of DKC1 in various cancers. Methods: We searched Web of Science, Embase, PubMed, Wanfang and CNKI. Stata SE15.1 was used to calculate the hazard ratio and relative risk with 95% CIs to assess the possible correlations between DKC1 expression levels and overall and disease-free survival, as well as with clinicopathological parameters. Results: We included nine studies, with a total of 2574 patients. There was a meaningful link between elevated DKC1 and poorer disease-free (p < 0.001) and overall survival (p < 0.001). Also, it was linked to advanced tumor node metastasis stage (p = 0.005). Conclusion: High DKC1 expression was predictive of worse prognosis and poorer clinicopathological parameters.

[1]  Rong Li,et al.  Gene signature to predict prognostic survival of hepatocellular carcinoma , 2022, Open medicine.

[2]  Gong Chen,et al.  Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells , 2021, Advanced science.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  Zhe Qiao,et al.  LncRNA PCAT1 Interacts with DKC1 to Regulate Proliferation, Invasion and Apoptosis in NSCLC Cells via the VEGF/AKT/Bcl2/Caspase9 Pathway , 2021, Cell transplantation.

[5]  G. Saretzki,et al.  Aberrant Dyskerin Expression Is Related to Proliferation and Poor Survival in Endometrial Cancer , 2021, Cancers.

[6]  Chunjie Sheng,et al.  Inhibition of DKC1 induces telomere-related senescence and apoptosis in lung adenocarcinoma , 2020, Journal of translational medicine.

[7]  A. Green,et al.  The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer , 2020, British Journal of Cancer.

[8]  A. Tewari,et al.  Pseudouridine as a novel biomarker in prostate cancer. , 2020, Urologic oncology.

[9]  Yong Duan,et al.  LncRNA MEG3 inhibits non-small cell lung cancer via interaction with DKC1 protein , 2020, Oncology letters.

[10]  P. Hou,et al.  DKC1 enhances angiogenesis by promoting HIF-1α transcription and facilitates metastasis in colorectal cancer , 2019, British Journal of Cancer.

[11]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[12]  G. Brandi,et al.  Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness , 2015, Histopathology.

[13]  Hong Wang,et al.  Unraveling secrets of telomeres: one molecule at a time. , 2014, DNA repair.

[14]  L. Montanaro,et al.  Inhibition of Human Dyskerin as a New Approach to Target Ribosome Biogenesis , 2014, PloS one.

[15]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[16]  A. Muñoz-Barrutia,et al.  Multiscale in situ analysis of the role of dyskerin in lung cancer cells. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[17]  G. Zamolo,et al.  Modulating telomerase activity in tumor patients by targeting dyskerin binding site for hTR. , 2012, Medical hypotheses.

[18]  Hui Liu,et al.  Dyskerin Overexpression in Human Hepatocellular Carcinoma Is Associated with Advanced Clinical Stage and Poor Patient Prognosis , 2012, PloS one.

[19]  A. Bertuch,et al.  Dyskeratosis congenita as a disorder of telomere maintenance. , 2012, Mutation research.

[20]  L. Montanaro.  Dyskerin and cancer: more than telomerase. The defect in mRNA translation helps in explaining how a proliferative defect leads to cancer , 2010, The Journal of pathology.

[21]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[22]  David B. Wilson,et al.  Dyskeratosis congenita , 2010, FEBS letters.

[23]  R. DePinho,et al.  Telomeres and telomerase in cancer. , 2010, Carcinogenesis.

[24]  R Engers,et al.  DKC1 overexpression associated with prostate cancer progression , 2009, British Journal of Cancer.

[25]  I. Dokal,et al.  Advances in the understanding of dyskeratosis congenita , 2009, British journal of haematology.

[26]  L. Montanaro,et al.  Nucleolus, ribosomes, and cancer. , 2008, The American journal of pathology.

[27]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[28]  N. Bache,et al.  Protein Composition of Catalytically Active Human Telomerase from Immortal Cells , 2007, Science.

[29]  J. Clohessy,et al.  Dyskerin expression influences the level of ribosomal RNA pseudo‐uridylation and telomerase RNA component in human breast cancer , 2006, The Journal of pathology.

[30]  W. Park,et al.  Absence of DKC1 exon 3 mutation in common human cancers. , 2006, Acta oncologica.

[31]  N. Carter,et al.  A DNA damage checkpoint response in telomere-initiated senescence , 2003, Nature.

[32]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[33]  A. Cheng,et al.  Differential regulation of telomerase activity by six telomerase subunits. , 2002, European journal of biochemistry.

[34]  T. Vulliamy,et al.  Dyskeratosis Congenita (DC) Registry: identification of new features of DC , 1998, British journal of haematology.

[35]  S. Klauck,et al.  X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions , 1998, Nature Genetics.

[36]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[37]  T. Vulliamy,et al.  Fine mapping of the dyskeratosis congenita locus in Xq28. , 1996, Journal of medical genetics.

[38]  J. Shay,et al.  The reactivation of telomerase activity in cancer progression. , 1996, Trends in genetics : TIG.

[39]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[40]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[41]  J. Steitz,et al.  Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. , 1992, The EMBO journal.

[42]  H. Cooke,et al.  In vivo loss of telomeric repeats with age in humans. , 1991, Mutation research.

[43]  Robin C. Allshire,et al.  Telomere reduction in human colorectal carcinoma and with ageing , 1990, Nature.

[44]  C. Harley,et al.  Telomeres shorten during ageing of human fibroblasts , 1990, Nature.

[45]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.